Cancer Institute of New Jersey
Cancer Institute of New Jersey
Cancer Specialties: The Cancer Institute of New Jersey (CINJ) is dedicated to improving the prevention, detection, treatment, and care of patients with cancer (such as breast, mesothelioma, thoracic cancers, etc.), through the transformation of laboratory discoveries into clinical practice.
Primary location:
Cancer Institute of New Jersey
Robert Wood Johnson Medical School
195 Little Albany Street
New Brunswick, NJ 089032681
Phone: (732) 235-2465
URL: http://www.cinj.org/
Facebook: http://www.facebook.com/pages/The-Cancer-Institute-of-New-Jersey-CINJ/85621141568
YouTube: http://www.youtube.com/user/CancerInstNJ#p/a/2/jGTeAJbj0DE
About the Cancer Institute of New Jersey:
As one of the nation’s 40 National Cancer Institute-designated Comprehensive Cancer Centers and the only one in New Jersey, The Cancer Institute of New Jersey (CINJ) delivers advanced comprehensive care to adults and children, and conducts cutting-edge cancer research. Our researchers and physicians transform discoveries into clinical practice and provide education and outreach regarding cancer prevention, detection and treatment.
Through our Network of hospitals, the reach of CINJ is statewide providing the best cancer care and the most advanced treatment options through-out the state, quite literally bringing research to life across New Jersey, the nation and beyond.
The Thoracic Oncology Program is a multidisciplinary program for cancer of the lung, pleura and medistinum. The healthcare team is comprised of a thoracic surgeon, radiologists, radiation oncologists, medical oncologists, nurses and social workers who work together to treat patients with cancers originating in the chest and lung (small cell lung cancer and non-small cell lung cancer), mesotheliomas, thyomas and upper esophageal cancers.
Patients are evaluated for clinical needs and for surgical, radiation therapy and chemotherapy options as well as opportunities for participation in clinical trials. Multimodality treatments are planned together, and approaches for optimal local control and symptom treatments are designed.
We are actively involved in developing innovative approaches and participate in national and international studies. In collaboration with our new drug programs we also work on bringing new agents into trials in thoracic cancer.
